Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder

Pharmacogenetics of antidepressant response

(2014) Stefano Porcelli et al.   JOURNAL OF PSYCHIATRY & NEUROSCIENCE

Genetics and Personalized Medicine in Antidepressant Treatment

(2012) Katarina Gvozdic et al.   CURRENT PHARMACEUTICAL DESIGN

The AmpliChip® CYP450 Test and Response to Treatment in Schizophrenia and Obsessive Compulsive Disorder: A Pilot Study and Focus on Cases with Abnormal CYP2D6 Drug Metabolism

(2012) Daniel J. Müller et al.   Genetic Testing and Molecular Biomarkers

Evidence-based pharmacotherapy of obsessive-compulsive disorder

(2012) Naomi A. Fineberg et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function

(2012) J C Stingl et al.   MOLECULAR PSYCHIATRY

Antidepressant Treatment and Altered CYP2D6 Activity

(2011) Inna D’empaire et al.   Journal of Psychiatric Practice

CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP

(2011) Patricia Huezo-Diaz et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Pharmacogenetics of obsessive–compulsive disorders

(2011) Eva J Brandl et al.   PHARMACOGENOMICS

Residual effects of esmirtazapine on actual driving performance: overall findings and an exploratory analysis into the role of CYP2D6 phenotype

(2011) Johannes G. Ramaekers et al.   PSYCHOPHARMACOLOGY

Will a New Genotyping Test Help the Clinician Predict Response to Antidepressant Drugs?

(2010) Gordon Parker et al.   Australasian Psychiatry

Composite Functional Genetic and Comedication CYP2D6 Activity Score in Predicting Tamoxifen Drug Exposure Among Breast Cancer Patients

(2010) Silvana Borges et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Cytochrome P450 2D6 Phenotype Predicts Antidepressant Efficacy of Venlafaxine

(2010) Kasia W. Lobello et al.   JOURNAL OF CLINICAL PSYCHIATRY

CYP2D6 genotype and smoking influence fluvoxamine steady-state concentration in Japanese psychiatric patients: lessons for genotype–phenotype association study design in translational pharmacogenetics

(2010) Yutaro Suzuki et al.   JOURNAL OF PSYCHOPHARMACOLOGY

CYP2D6 in the brain: genotype effects on resting brain perfusion

(2010) J Kirchheiner et al.   MOLECULAR PSYCHIATRY

CYP2C19 variation and citalopram response

(2010) David A. Mrazek et al.   Pharmacogenetics and Genomics

Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response

(2010) Ming-Hsien Tsai et al.   PHARMACOGENOMICS

CYP2D6 polymorphism in patients with eating disorders

(2010) E M Peñas-LLedó et al.   PHARMACOGENOMICS JOURNAL

Effect of Cytochrome P450 Enzyme Polymorphisms on Pharmacokinetics of Venlafaxine

(2010) Donald E McAlpine et al.   THERAPEUTIC DRUG MONITORING

Variation in theCYP2D6gene is associated with a lower serum sodium concentration in patients on antidepressants

(2009) Sonja Kwadijk-de Gijsel et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

High Frequency of Occurrence of CYP2D6 Gene Duplication/Multiduplication Indicating Ultrarapid Metabolism Among Suicide Cases

(2009) A L Zackrisson et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients

(2009) Alessandro Serretti et al.   INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

Response to serotonin reuptake inhibitors in OCD is not influenced by common CYP2D6 polymorphisms

(2009) Filip C.W. Van Nieuwerburgh et al.   INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE

Venlafaxine Metabolism as a Marker of Cytochrome P450 Enzyme 2D6 Metabolizer Status

(2009) Alice I. Nichols et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder

(2009) M H Bloch et al.   MOLECULAR PSYCHIATRY

When is Pharmacogenetic Testing for Antidepressant Response Ready for the Clinic? A Cost-effectiveness Analysis Based on Data from the STAR*D Study

(2009) Roy H Perlis et al.   NEUROPSYCHOPHARMACOLOGY

The CYP2C19*17 genotype is associated with lower imipramine plasma concentrations in a large group of depressed patients

(2009) P W Schenk et al.   PHARMACOGENOMICS JOURNAL

Pharmacogenomics of antidepressant drugs

(2009) Sonja Horstmann et al.   PHARMACOLOGY & THERAPEUTICS

Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of antidepressants

(2008) Monique J. Bijl et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Serum concentrations of sertraline and N-desmethyl sertraline in relation to CYP2C19 genotype in psychiatric patients

(2008) I. Rudberg et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Cerebral activation in children and adolescents with obsessive–compulsive disorder before and after treatment: A functional MRI study

(2008) Luisa Lázaro et al.   JOURNAL OF PSYCHIATRIC RESEARCH

Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder

(2008) M Kato et al.   MOLECULAR PSYCHIATRY

The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication

(2008) A M Ruscio et al.   MOLECULAR PSYCHIATRY

Pharmacokinetic Genes Do Not Influence Response or Tolerance to Citalopram in the STAR*D Sample

(2008) Eric J. Peters et al.   PLoS One